메뉴 건너뛰기




Volumn 37, Issue 2, 2015, Pages 243-249

Effect of CYP2C19 polymorphisms on stiripentol administration in Japanese cases of Dravet syndrome

Author keywords

Clobazam; CYP2C19 polymorphisms; Dravet syndrome; Norclobazam; Stiripentol

Indexed keywords

CLOBAZAM; CLONAZEPAM; CYTOCHROME P450 2C19; NORCLOBAZAM; POTASSIUM BROMIDE; STIRIPENTOL; VALPROIC ACID; 1,3 DIOXOLANE DERIVATIVE; ANTICONVULSIVE AGENT;

EID: 84920672322     PISSN: 03877604     EISSN: 18727131     Source Type: Journal    
DOI: 10.1016/j.braindev.2014.04.003     Document Type: Article
Times cited : (14)

References (18)
  • 1
    • 84865462085 scopus 로고    scopus 로고
    • Stiripentol: an example of antiepileptic drug development in childhood epilepsies
    • Nabbout R., Chiron C. Stiripentol: an example of antiepileptic drug development in childhood epilepsies. Eur J Paediatr Neurol 2012, 16:S13-S17.
    • (2012) Eur J Paediatr Neurol , vol.16 , pp. S13-S17
    • Nabbout, R.1    Chiron, C.2
  • 2
    • 0032724018 scopus 로고    scopus 로고
    • Stiripentol: efficacy and tolerability in children with epilepsy
    • Perez J., Chiron C., Musial C., Rey E., Blehaut H., d'Athis P., et al. Stiripentol: efficacy and tolerability in children with epilepsy. Epilepsia 1999, 40:1618-1626.
    • (1999) Epilepsia , vol.40 , pp. 1618-1626
    • Perez, J.1    Chiron, C.2    Musial, C.3    Rey, E.4    Blehaut, H.5    d'Athis, P.6
  • 3
    • 0034638786 scopus 로고    scopus 로고
    • Stiripentol in severe myoclonic epilepsy in infancy: a randomised placebo-controlled syndrome-dedicated trial
    • Chiron C., Marchand M.C., Tran A., Rey E., d'Athis P., Vincent J., et al. Stiripentol in severe myoclonic epilepsy in infancy: a randomised placebo-controlled syndrome-dedicated trial. Lancet 2000, 356:1638-1642.
    • (2000) Lancet , vol.356 , pp. 1638-1642
    • Chiron, C.1    Marchand, M.C.2    Tran, A.3    Rey, E.4    d'Athis, P.5    Vincent, J.6
  • 4
    • 33645106149 scopus 로고    scopus 로고
    • In vitro and in vivo inhibitory effect of stiripentol on clobazam metabolism
    • Giraud C., Treluyer J.M., Rey E., Chiron C., Vincent J., Pons G., et al. In vitro and in vivo inhibitory effect of stiripentol on clobazam metabolism. Drug Metab Dispos 2006, 34:608-611.
    • (2006) Drug Metab Dispos , vol.34 , pp. 608-611
    • Giraud, C.1    Treluyer, J.M.2    Rey, E.3    Chiron, C.4    Vincent, J.5    Pons, G.6
  • 5
    • 70350401140 scopus 로고    scopus 로고
    • Stiripentol open study in Japanese patients with Dravet syndrome
    • Inoue Y., Ohtsuka Y., Oguni H., Tohyama J., Baba H., Fukushima K., et al. Stiripentol open study in Japanese patients with Dravet syndrome. Epilepsia 2009, 50:2362-2368.
    • (2009) Epilepsia , vol.50 , pp. 2362-2368
    • Inoue, Y.1    Ohtsuka, Y.2    Oguni, H.3    Tohyama, J.4    Baba, H.5    Fukushima, K.6
  • 6
    • 15444340367 scopus 로고    scopus 로고
    • A new genetic defect in human CYP2C19: mutation of the initiation codon is responsible for poor metabolism of S-mephenytoin
    • Ferguson R.J., De Morais S.M., Benhamou S., Bouchardy C., Blaisdell J., Ibeanu G., et al. A new genetic defect in human CYP2C19: mutation of the initiation codon is responsible for poor metabolism of S-mephenytoin. J Pharmacol Exp Ther 1998, 284:356-361.
    • (1998) J Pharmacol Exp Ther , vol.284 , pp. 356-361
    • Ferguson, R.J.1    De Morais, S.M.2    Benhamou, S.3    Bouchardy, C.4    Blaisdell, J.5    Ibeanu, G.6
  • 7
    • 7744226277 scopus 로고    scopus 로고
    • A major influence of CYP2C19 genotype on the steady-state concentration of N-desmethylclobazam
    • Kosaki K., Tamura K., Sato R., Samejima H., Tanigawara Y., Takahashi T. A major influence of CYP2C19 genotype on the steady-state concentration of N-desmethylclobazam. Brain Dev 2004, 26:530-534.
    • (2004) Brain Dev , vol.26 , pp. 530-534
    • Kosaki, K.1    Tamura, K.2    Sato, R.3    Samejima, H.4    Tanigawara, Y.5    Takahashi, T.6
  • 8
    • 43349103389 scopus 로고    scopus 로고
    • A screening test for the prediction of Dravet syndrome before one year of age
    • Hattori J., Ouchida M., Ono J., Miyake S., Maniwa S., Mimaki N., et al. A screening test for the prediction of Dravet syndrome before one year of age. Epilepsia 2008, 49:626-633.
    • (2008) Epilepsia , vol.49 , pp. 626-633
    • Hattori, J.1    Ouchida, M.2    Ono, J.3    Miyake, S.4    Maniwa, S.5    Mimaki, N.6
  • 9
    • 0344672944 scopus 로고    scopus 로고
    • Mutations of sodium channel alpha subunit type 1 (SCN1A) in intractable childhood epilepsies with frequent generalized tonic-clonic seizures
    • Fujiwara T., Sugawara T., Mazaki-Miyazaki E., Takahashi Y., Fukushima K., Watanabe M., et al. Mutations of sodium channel alpha subunit type 1 (SCN1A) in intractable childhood epilepsies with frequent generalized tonic-clonic seizures. Brain 2003, 126:531-546.
    • (2003) Brain , vol.126 , pp. 531-546
    • Fujiwara, T.1    Sugawara, T.2    Mazaki-Miyazaki, E.3    Takahashi, Y.4    Fukushima, K.5    Watanabe, M.6
  • 10
    • 10744227466 scopus 로고    scopus 로고
    • + channel alpha 1 subunit gene SCN1A in core severe myoclonic epilepsy in infancy (SMEI) and in borderline SMEI (SMEB)
    • + channel alpha 1 subunit gene SCN1A in core severe myoclonic epilepsy in infancy (SMEI) and in borderline SMEI (SMEB). Epilepsia 2004, 45:140-148.
    • (2004) Epilepsia , vol.45 , pp. 140-148
    • Fukuma, G.1    Oguni, H.2    Shirasaka, Y.3    Watanabe, K.4    Miyajima, T.5    Yasumoto, S.6
  • 11
    • 6944252142 scopus 로고    scopus 로고
    • In vitro characterization of clobazam metabolism by recombinant cytochrome p450 enzymes: importance of CYP2C19
    • Giraud C., Tran A., Rey E., Vincent J., Tréluyer J.M., Pons G. In vitro characterization of clobazam metabolism by recombinant cytochrome p450 enzymes: importance of CYP2C19. Drug Metab Dispos 2004, 32:1279-1286.
    • (2004) Drug Metab Dispos , vol.32 , pp. 1279-1286
    • Giraud, C.1    Tran, A.2    Rey, E.3    Vincent, J.4    Tréluyer, J.M.5    Pons, G.6
  • 12
    • 35648994906 scopus 로고    scopus 로고
    • Efficacy of low-dose, add-on therapy of clobazam(CLB) is produced by its major metabolite, N-desmethyl-CLB
    • Kinoshita M., Ikeda A., Begum T., Terada K., Shibasaki H. Efficacy of low-dose, add-on therapy of clobazam(CLB) is produced by its major metabolite, N-desmethyl-CLB. J Neurol Sci 2007, 263:44-48.
    • (2007) J Neurol Sci , vol.263 , pp. 44-48
    • Kinoshita, M.1    Ikeda, A.2    Begum, T.3    Terada, K.4    Shibasaki, H.5
  • 13
    • 58049084097 scopus 로고    scopus 로고
    • A receptor as a positive allosteric modulator
    • A receptor as a positive allosteric modulator. Neuropharmacology 2009, 56:190-197.
    • (2009) Neuropharmacology , vol.56 , pp. 190-197
    • Fisher, J.L.1
  • 14
    • 79953728248 scopus 로고    scopus 로고
    • A receptors
    • A receptors. Epilepsia 2011, 52:76-78.
    • (2011) Epilepsia , vol.52 , pp. 76-78
    • Fisher, J.L.1
  • 17
    • 79955022433 scopus 로고    scopus 로고
    • Current therapeutic procedures in Dravet syndrome
    • Chiron C. Current therapeutic procedures in Dravet syndrome. Dev Med Child Neurol 2011, 53:16-18.
    • (2011) Dev Med Child Neurol , vol.53 , pp. 16-18
    • Chiron, C.1
  • 18
    • 79959974462 scopus 로고    scopus 로고
    • Ketogenic diet also benefits Dravet syndrome patients receiving stiripentol: a prospective pilot study
    • Nabbout R., Copioli C., Chipaux M., Chemaly N., Desguerre I., Dulac O., et al. Ketogenic diet also benefits Dravet syndrome patients receiving stiripentol: a prospective pilot study. Epilepsia 2011, 52:e54-e57.
    • (2011) Epilepsia , vol.52 , pp. e54-e57
    • Nabbout, R.1    Copioli, C.2    Chipaux, M.3    Chemaly, N.4    Desguerre, I.5    Dulac, O.6


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.